Natriuretic Peptide A Proteins (NPPA)

Rainbow Trout (Oncorhynchus mykiss) Natriuretic Peptide A (NPPA) interaction partners

1. Expression of atrial natriuretic peptide, C-type natriuretic peptide-1, and the guanylyl cyclase-linked (GC) natriuretic peptide receptor-A and -B-type receptors was determined by PCR from the mRNA of head kidney leucocytes

2. Rainbow trout cardiac natriuretic peptides and their receptors respond principally to volume, not salt overload, suggesting that their primary function is to protect the heart.

Pig (Porcine) Natriuretic Peptide A (NPPA) interaction partners

1. Atrial natriuretic peptide and vasopressin-presence in the ciliary body of eye in the pig (sus domesticus).

2. ANP and BNP gene expression differs considerably between cardiac chambers in the first 72 hours of life in healthy piglets, resembling the transition from fetal to neonate circulation. The cardiac gene expression does not explain plasma concentrations.

3. Up-regulation of ANP and a reduction in a ratio of sarcoplasmic reticulum calcium ATPase 2a and phospholamban in failing myocardium are observed in a porcine model of tachycardia.

4. Arial natriuretic factor (ANF) and N-terminal proANF may be better suited than brain natriuretic peptide as markers of cardiac preload during the development and treatment of acute heart failure.

5. Stimulation of prepubertal granulosa cells with FSH resulted in a moderate expression of ANP. When FSH treatment was followed by LH, the pronounced expression of ANP was observed in all cells.

Horse (Equine) Natriuretic Peptide A (NPPA) interaction partners

1. ANP in plasma is increased in horses with heart disease associated with altered left-sided chamber dimensions and/or function.

2. Cardiac ANP was increased in horses with mitral regurgitation (MR) and cardiac troponin levels were low in healthy and MR affected horses.

Human Natriuretic Peptide A (NPPA) interaction partners

1. Observed increased residual platelet reactivity exclusively in diabetic carriers of the T2238C ANP variant undergoing elective PCI, suggesting the need of a more effective platelet inhibition in this category of patients.

2. platelet aggregation resulted to be higher in patients with atrial fibrillation carrying the C2238 ANP gene variant with respect to non-carriers. In conclusions, C2238/alphaANP promotes platelet aggregation through the activation of Nox2 and the reduction of cAMP.

3. The results of our study demonstrated that the effect of NPPA SNPs rs5063 and rs198358 on central obesity might be modified by smoking in the Chinese Han population.

4. Upon cardiac stress, Nppa and Nppb are strongly upregulated in the ventricular myocardium. (Review)

5. Suggest that pro-ANP/corin/NPR-C signaling is dominant in the vascular system in preeclampsia.

6. Data indicate the blood pressure-lowering effect of atrial natriuretic peptide (ANP) in the general population.

7. Low circulating MR-proANP at the time of device implantation is associated with cardiac resynchronization therapy response and more favourable outcome.

8. An increase in year-by-year BP variability over the past 6 years is associated with elevated plasma levels of ANP and BNP in the Japanese general population.

9. High plasma levels of MR-proANP are associated with the incidence of atrial fibrillation and stroke in the middle-aged and elderly population.

10. The young adults displayed significant negative associations between MR-proANP and several components of the metabolic syndrome, whereas such associations were not found among the adolescents besides triglycerides and diastolic BP.

11. In summary, there were no significant differences in ANP and BNP levels after percutaneous epicardial left atrial appendage suture ligation using LARIAT device 3 months after procedure.

12. NPPA SNPs were not associated with insulin resistance in older adults.

13. TIMP-4, NT-proANP, NT-proBNP were strongest associated with PAF and AHRE. The discriminatory performance of CHADS2-VASc for PAF was increased by addition of selected biomarkers.

14. the G allele of the genetic variant rs5068 in African Americans is associated with lower prevalence of metabolic syndrome and lower triglycerides values

15. ANP inhibits TGF-beta1-induced EMT in 16HBE-14o and A549 cells through cGMP/PKG signaling, by which it targets TGF-beta1/Smad3 via attenuating phosphorylation of Smad3. These findings suggest the potential of ANP in the treatment on pulmonary diseases with airway remodeling.

16. the ANP T1766C gene polymorphism may be associated with the risk of essential hypertension, and the 1766C allele may be a protective factor against the disease

17. increased plasma proANP should be a protective factor of hyperuricemia among middle-aged and old women

18. Midregional-proANP could accurately detect HF in children and adolescents. Its diagnostic performance was comparable with that of NT-proBNP, regardless of the underlying condition.

19. Corin and atrial natriuretic peptide A were most abundant in the proximal convoluted tubules and the medullary connecting ducts.

20. This study indicates that in children with community-acquired pneumonia, sTREM-1, Midregional-proANP, and Midregional-proADM blood levels have poor abilities to differentiate bacterial from viral diseases or to identify severe cases.

Cow (Bovine) Natriuretic Peptide A (NPPA) interaction partners

1. ANP acts as an anti-permeability factor by inhibiting the signaling functions of vascular permeability factor and by preserving the endothelial cell tight junctions functional morphology

Rabbit Natriuretic Peptide A (NPPA) interaction partners

1. These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system.

2. Diabetes may modify the vascular actions of ANP in isolated rabbit carotid arteries and the mechanisms involved in these actions; ANP induces relaxation of precontracted carotid arteries, which is lower in diabetic than in control rabbits.

3. The study suggests that Beta1-adrenergic receptor activation decreases atrial natriuretic peptide release via cAMP- and Ca(2+)-dependent mechanisms.

Mouse (Murine) Natriuretic Peptide A (NPPA) interaction partners

1. Endogenous ANP/guanylyl cyclase-A signaling improves the initial adaptative response of beta-cells to high fat diet-induced obesity. Impaired beta-cell ANP/GC-A signaling in obese individuals might contribute to the development of type 2 diabetes.

2. data demonstrate that gestational hypertension and lack of maternal ANP did not significantly impact the progression and regression of pregnancy-induced cardiac hypertrophy over gestation and postpartum in ANP(+/-) offspring.

3. The present study provides a novel insight into the potential underlying mechanisms of telmisartan-induced inhibition of cardiomyocyte hypertrophy, which involves inhibition of NFAT activation, nuclear translocation and the ANP/BNP cascade.

4. the developmental regulation and stress response of the Nppa-Nppb cluster involve the concerted action of multiple enhancers and epigenetic changes distributed across a structurally rigid regulatory domain.

5. we investigated pregnancies of ANP wild type, heterozygous, and knockout mice. Maternal blood pressure did not differ between genotypes, and fetal weight was unaffected. Placental weight was greater in ANP(-/-) versus ANP(+/+) mice. Therefore, in our hands, the ANP model does not express phenotypic features of preeclampsia with fetal growth restriction.

6. Data (including data from studies in knockout mice) suggest expression of ANP/BNP/GC-A (atrial natriuretic peptide, brain natriuretic peptide, and guanylyl cyclase-A) is important in embryonic neovascularization and organogenesis.

7. Goalpha plays a role in ANF sorting during intracellular vectorial transport and with the presence of a mechanism that preserves the molar relationship between cellular ANF and BNP.

8. ANP prevents cancer metastasis by inhibiting the adhesion of tumor cells to inflamed endothelial cells

9. Expression of NPPA splice variants is differentially regulated in the developing mouse heart.

10. NPPA acts on the NPR1 receptor, is expressed in mouse dorsal root and trigeminal ganglia, and the spinal cord.

11. Natriuretic peptides buffer renin-dependent hypertension.

12. Data indicate that the identified stress-responsive enhancer of Nppa and Nppb, the most common markers of heart failure, is a 650-bp fragment within 50 kb of the Nppa and Nppb loci.

13. Absence of maternal atrial natriuretic peptide leads to gestational hypertension and adaptive changes fetal cardiac growth and blood pressure regulation.

14. This study investigated a novel mechanism of vascular barrier protection by ANP via modulation of GEF-H1 function.

15. Data indicate that NRG-1beta up-regulated the gene expressions of Nkx2.5, GATA4, alpha-actin, MLC-2v, and ANF in a time-dependent regulation of ErbB/ERK1/2 pathways.

16. Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-AKT signaling pathways.

17. there is a gut-heart GLP-1R-dependent and ANP-dependent axis that regulates blood pressure and involves Epac2

18. Characterize an estradiol-regulated interaction of NPPA with ERalpha in cardiomyocytes.

19. Data show that KO/TgV mice had significantly higher levels of proatrial natriuretic peptide in the heart compared with that in control KO/TgWT mice, indicating that the corin variant was defective in processing natriuretic peptides in vivo.

20. PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart.